Published in Leuk Lymphoma on August 01, 1995
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood (2011) 7.49
Depletion of CD4(+) T cells causes reactivation of murine persistent tuberculosis despite continued expression of interferon gamma and nitric oxide synthase 2. J Exp Med (2000) 3.20
Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother (2009) 2.35
Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol (1998) 2.21
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol (2013) 1.91
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood (2015) 1.53
Anti-CD19 and anti-CD22 monoclonal antibodies increase the effectiveness of chemotherapy in Pre-B acute lymphoblastic leukemia cell lines. Leuk Res (2007) 1.52
Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer (2016) 1.51
Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med (2012) 1.40
Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin Immunopathol (2006) 1.24
CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.24
Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc Natl Acad Sci U S A (2005) 1.15
Toward targeting B cell cancers with CD4+ CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis. J Exp Med (2008) 1.14
CD19-CAR trials. Cancer J (2014) 1.09
CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis. J Clin Invest (2012) 1.09
A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice. J Immunol (2012) 0.99
Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy. Clin Cancer Res (2016) 0.95
Simplified process for the production of anti-CD19-CAR-engineered T cells. Cytotherapy (2013) 0.95
Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity. Arthritis Res Ther (2012) 0.91
Monoclonal antibodies in acute lymphoblastic leukemia. Blood (2015) 0.88
Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies. Clin Cancer Res (2015) 0.88
CAR-T Cell Therapy for Lymphoma. Annu Rev Med (2015) 0.86
A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies. J Hematol Oncol (2014) 0.85
A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood (2014) 0.84
Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells. Oncotarget (2016) 0.82
Immunophenotyping of acute lymphoblastic leukaemia in routinely processed bone marrow biopsy specimens. J Clin Pathol (1999) 0.81
Targeting CD19 in B-cell lymphoma: emerging role of SAR3419. Cancer Manag Res (2013) 0.79
Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials. J Ocul Pharmacol Ther (2015) 0.79
Efficient B cell depletion via diphtheria toxin in CD19-Cre/iDTR mice. PLoS One (2013) 0.78
A comparison of the anti-tumor effects of a chimeric versus murine anti-CD19 immunotoxins on human B cell lymphoma and Pre-B acute lymphoblastic leukemia cell lines. Toxins (Basel) (2011) 0.78
Chimeric antigen receptor-modified T cells strike back. Int Immunol (2016) 0.76
An anti-CD19 antibody coupled to a tetanus toxin peptide induces efficient Fas ligand (FasL)-mediated cytotoxicity of a transformed human B cell line by specific CD4+ T cells. Clin Exp Immunol (1998) 0.76
Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist. Oncologist (2016) 0.75
Chimeric Antigen Receptor T Cell Therapy in Hematology. Turk J Haematol (2015) 0.75
Clinical targeting recombinant immunotoxins for cancer therapy. Onco Targets Ther (2017) 0.75
CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol (2001) 1.30
Lyn tyrosine kinase signals cell cycle arrest but not apoptosis in B-lineage lymphoma cells. Proc Natl Acad Sci U S A (1994) 1.01
Tumour dormancy and cell signalling--III: Role of hypercrosslinking of IgM and CD40 on the induction of cell cycle arrest and apoptosis in B lymphoma cells. Ther Immunol (1995) 0.92
Tumor dormancy and cell signaling. V. Regrowth of the BCL1 tumor after dormancy is established. Blood (1997) 0.89
Role of antibody signaling in inducing tumor dormancy. Adv Exp Med Biol (1996) 0.75
Lyn tyrosine kinase signals cell cycle arrest in mouse and human B-cell lymphoma. Curr Top Microbiol Immunol (1995) 0.75